Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Pemetrexed Plus Cisplatin in Malignant Pleural Mesothelioma
NCT00386815Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in malignant pleural mesothelioma (MPM), sponsored by Eli Lilly and Company. Primary endpoint: Safety profile. Started Oct 2006; status: completed.
02
Drugs
pemetrexed
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00386815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386815.